These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 23600973)
21. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H; BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914 [TBL] [Abstract][Full Text] [Related]
22. Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells. Iwamoto Y; Ishii K; Sasaki T; Kato M; Kanda H; Yamada Y; Arima K; Shiraishi T; Sugimura Y Cancer Prev Res (Phila); 2013 Sep; 6(9):1000-6. PubMed ID: 23901046 [TBL] [Abstract][Full Text] [Related]
23. Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil. Tanaka N; Torimoto K; Asakawa I; Miyake M; Anai S; Hirayama A; Hasegawa M; Konishi N; Fujimoto K Radiat Oncol; 2014 Dec; 9():302. PubMed ID: 25544509 [TBL] [Abstract][Full Text] [Related]
24. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Guo Y; Kyprianou N Cancer Res; 1999 Mar; 59(6):1366-71. PubMed ID: 10096572 [TBL] [Abstract][Full Text] [Related]
25. Effect of naftopidil on nocturia after failure of tamsulosin. Oh-oka H Urology; 2008 Nov; 72(5):1051-5. PubMed ID: 18817955 [TBL] [Abstract][Full Text] [Related]
26. Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction. Takeda M; Homma Y; Araki I; Kakizaki H; Yamanishi T; Yokota T; Gotoh M; Igawa Y; Seki N; Takei M; Yoshida M; Sugaya K; Nishizawa O; BJU Int; 2011 Jul; 108(1):100-7. PubMed ID: 21062392 [TBL] [Abstract][Full Text] [Related]
27. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype-selective antagonist naftopidil in benign prostate hyperplasia patients. Kojima Y; Sasaki S; Shinoura H; Hayase M; Kubota Y; Hayashi Y; Tsujimoto G; Kohri K Prostate; 2007 Sep; 67(12):1285-92. PubMed ID: 17626248 [TBL] [Abstract][Full Text] [Related]
28. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Tahmatzopoulos A; Kyprianou N Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869 [TBL] [Abstract][Full Text] [Related]
29. Combination treatment with naftopidil increases the efficacy of radiotherapy in PC-3 human prostate cancer cells. Iwamoto Y; Ishii K; Kanda H; Kato M; Miki M; Kajiwara S; Arima K; Shiraishi T; Sugimura Y J Cancer Res Clin Oncol; 2017 Jun; 143(6):933-939. PubMed ID: 28243746 [TBL] [Abstract][Full Text] [Related]
30. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417 [TBL] [Abstract][Full Text] [Related]
31. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells. Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395 [TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo. Huang JJ; Cai Y; Yi YZ; Huang MY; Zhu L; He F; Liu XW; Huang BY; Yuan M Eur J Pharmacol; 2016 Nov; 791():473-481. PubMed ID: 27615445 [TBL] [Abstract][Full Text] [Related]
33. In vivo study on the effects of alpha1-adrenoceptor antagonists on intraurethral pressure in the prostatic urethra and intraluminal pressure in the vas deferens in male dogs. Noguchi Y; Ohtake A; Suzuki M; Sasamata M Eur J Pharmacol; 2008 Feb; 580(1-2):256-61. PubMed ID: 18078926 [TBL] [Abstract][Full Text] [Related]
34. The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers. Batty M; Pugh R; Rathinam I; Simmonds J; Walker E; Forbes A; Anoopkumar-Dukie S; McDermott CM; Spencer B; Christie D; Chess-Williams R Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537875 [TBL] [Abstract][Full Text] [Related]
35. Piperazine-based Alpha-1 AR Blocker, Naftopidil, Selectively Suppresses Malignant Human Bladder Cells via Induction of Apoptosis. Nakagawa YU; Nagaya H; Miyata T; Wada Y; Oyama T; Gotoh A Anticancer Res; 2016 Apr; 36(4):1563-70. PubMed ID: 27069132 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the effects of four α1-adrenoceptor antagonists on ejaculatory function in rats. Tatemichi S; Kobayashi K; Yokoi R; Kobayashi K; Maruyama K; Hoyano Y; Kobayashi M; Kuroda J; Kusama H Urology; 2012 Aug; 80(2):486.e9-16. PubMed ID: 22676952 [TBL] [Abstract][Full Text] [Related]
37. [Ejaculatory disorder by alpha-1 adrenoceptor antagonist in patients with benign prostatic hyperplasia; retrospective comparison between naftopidil and tamsulosin]. Furuya R; Hisasue S; Ogura H; Furuya S; Masumori N; Itoh N; Tsukamoto T Hinyokika Kiyo; 2005 Nov; 51(11):763-6. PubMed ID: 16363711 [TBL] [Abstract][Full Text] [Related]
38. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Tatemichi S; Tomiyama Y; Maruyama I; Kobayashi S; Kobayashi K; Maezawa A; Kobayashi M; Yamazaki Y; Shibata N Neurourol Urodyn; 2006; 25(7):792-9; discussion 800-1. PubMed ID: 16894620 [TBL] [Abstract][Full Text] [Related]
39. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. Cuellar DC; Rhee J; Kyprianou N Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853 [TBL] [Abstract][Full Text] [Related]
40. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy. Yamaguchi S; Osanai H; Numata A; Watanabe M; Kakizaki H Int J Urol; 2013 May; 20(5):513-9. PubMed ID: 23078534 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]